Evidence map›Paper›PMID 40663138›Full record

ReviewIntensive care medicine2025

Preventing acute kidney injury and its longer-term impact in the critically ill.

Alexander Zarbock, Lui Forni, Jay L Koyner, Hernando Gómez, Neesh Pannu, Marlies Ostermann, Rinaldo Bellomo, John A Kellum, Thilo von Groote

Registry-linked trialAbstract readReview
In one paragraph

Review in Intensive care medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07617675 (Perioperative Recombinant Human Brain Natriuretic Peptide for Renal Protection in Cardiac Surgery), which is not on this map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07617675 phase4not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Perioperative Recombinant Human Brain Natriuretic Peptide for Renal Protection in Cardiac Surgery: the PROTECT-CS Randomized Clinical Trial

TypeinterventionalSponsorChina National Center for Cardiovascular DiseasesRan2026 to 2029Enrolled694ConditionsAKI - Acute Kidney Injury, Cardiac Surgical Procedures, Cardiopulmonary BypassArmsRecombinant Human Brain Natriuretic Peptide (rhBNP), Normal Saline (Placebo)
3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Impact of an Acute Kidney Injury Prevention Bundle in High-risk Intensive Care Unit Patients: A Single Center Before-After Study.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2026
    Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Alexander ZarbockDepartment of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Münster, Germany. zarbock@uni-muenster.de.ORCID 0000-0002-2124-1714
Lui ForniSchool of Medicine, University of Surrey and Royal Surrey Hospital, Guildford, Surrey, UK.
Jay L KoynerSection of Nephrology, Department of Medicine, University of Chicago, Chicago, USA.
Hernando GómezCenter for Critical Care Nephrology, University of Pittsburgh, Pittsburgh, USA.
Neesh PannuDivision of Nephrology, Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada.
Marlies OstermannDepartment of Intensive Care, Guy's & St Thomas' NHS Foundation Trust, London, UK.
Rinaldo BellomoDepartment of Intensive Care, Austin Hospital, Australian and New Zealand Intensive Care Research Centre, Monash University, Melbourne, Australia.
John A KellumCenter for Critical Care Nephrology, University of Pittsburgh, Pittsburgh, USA.
Thilo von GrooteDepartment of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Münster, Germany.

Funding

Deutsche Forschungsgemeinschaft ZA 428/21-1Deutsche Forschungsgemeinschaft ZA 428/29-1Deutsche Forschungsgemeinschaft ZA 428/30-1
6 · The paper itself

Abstract

Acute kidney injury (AKI) is a heterogeneous syndrome that not only affects short-term morbidity and mortality but also influences long-term outcomes. AKI is part of acute kidney disease (AKD) that encompasses a range of different conditions and is characterized by a kidney dysfunction lasting 90 days or less after which time the term chronic kidney disease (CKD) applies. AKD may result in irreversible loss of nephrons and may lead to CKD. In this narrative review, an update on different aspects of AKI in critically ill patients will be provided. We discuss biomarkers for early diagnosis of AKI, sub-clinical AKI, as well as AKI-AKD-CKD transition. In addition, various strategies to prevent the development of AKI, including the application of amino acids, remote-ischemic preconditioning, hemoadsorption, and a kidney prevention strategy, will be discussed. Finally, the choice of adequate endpoints for AKI prevention trials will be addressed."Take home message".AKI and even subclinical AKI impact short- and long-term outcome and therefore, prevention of kidney injury is of utmost importance. As several strategies have been proven to be effective in preventing the development of AKI, these therapies should be implemented in daily practice to improve patient outcomes.

Indexed as

Acute Kidney InjuryCritical IllnessBiomarkersEarly DiagnosisHumansRenal Insufficiency, ChronicBiomarkersAcute kidney diseaseAcute kidney injuryBiomarkersChronic kidney diseasePreventive strategy

Identifiers

PMID40663138
PMCPMC12283467

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.